BAY 3401016

DRUG2 trials

Sponsors

Bayer AG, Bayer

Conditions

Alport SyndromeChronic kidney disease

Phase 2

A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome

Active, not recruitingNCT07211685

BayerAlport Syndrome

Start: 2025-11-19End: 2027-11-29Target: 60Updated: 2026-09-18

(22419) A randomized, double-blind, placebo-controlled, parallel group Phase 2a study with an extension phase to evaluate the efficacy and safety of BAY 3401016 in participants aged 18 to 45 with Alport syndrome

Not yet recruitingCTIS2024-516471-33-00

Bayer AGAlport Syndrome, Chronic kidney disease

Target: 31Updated: 2026-01-20